United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 25.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,667 shares of the biotechnology company’s stock after selling 1,581 shares during the period. Oppenheimer & Co. Inc.’s holdings in United Therapeutics were worth $1,647,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Oregon Public Employees Retirement Fund grew its stake in shares of United Therapeutics by 0.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock valued at $3,214,000 after buying an additional 33 shares during the period. GraniteShares Advisors LLC purchased a new position in shares of United Therapeutics during the 4th quarter worth approximately $442,000. Denali Advisors LLC purchased a new position in shares of United Therapeutics during the 4th quarter worth approximately $495,000. Los Angeles Capital Management LLC boosted its position in shares of United Therapeutics by 14.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 103,597 shares of the biotechnology company’s stock worth $36,553,000 after purchasing an additional 13,030 shares during the period. Finally, Amalgamated Bank boosted its position in shares of United Therapeutics by 2.8% during the 4th quarter. Amalgamated Bank now owns 22,167 shares of the biotechnology company’s stock worth $7,821,000 after purchasing an additional 602 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction on Monday, February 10th. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $896,950.62. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Louis W. Sullivan sold 26,209 shares of the firm’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the transaction, the director now directly owns 5,051 shares in the company, valued at $1,885,134.22. The trade was a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 124,164 shares of company stock worth $45,278,893 in the last ninety days. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Trading Down 3.1 %

Shares of UTHR opened at $310.03 on Tuesday. United Therapeutics Co. has a twelve month low of $221.53 and a twelve month high of $417.82. The firm’s fifty day simple moving average is $358.58 and its 200-day simple moving average is $360.88. The firm has a market capitalization of $13.92 billion, a price-to-earnings ratio of 13.62, a PEG ratio of 0.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same period last year, the business earned $4.36 EPS. On average, analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

UTHR has been the subject of a number of research analyst reports. UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.